Truist Securities Reaffirms Buy Rating for Revolution Medicines
Truist Securities maintains a buy rating on Revolution Medicines, setting a $210 price target, a 12.13% upside from the current price.
Key Points
- On June 30, 2026, Truist Securities reiterated a buy rating for Revolution Medicines, Inc. (RVMD) with a price target of $210.
- Truist Securities's $210 price target implies 12.13% upside from Revolution Medicines, Inc.'s ($RVMD) current $187.28 share price.
- Shares of RVMD traded near $192.62 on Tuesday, with a market cap of approximately $38.7 billion and a 52-week high of $184.39.
- Several insiders, including the CFO, engaged in both planned and unplanned trades, while institutions like BlackRock increased their holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Truist Securities reiterated its buy rating on Revolution Medicines, Inc. (NasdaqGS: RVMD), setting a price target of $210. This reaffirmation by analyst Gregory Renza signals continued confidence in the biotechnology company's future prospects.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Revolution Medicines
Several institutional investors have been active in Revolution Medicines. Farallon Capital Management LLC reduced its holdings by 978,000 shares, ending with 13,604,796 shares valued at about $1.32 billion, representing a 6.7% decrease. BlackRock, Inc. increased its stake by 2,286,050 shares, now holding 11,212,706 shares worth approximately $1.09 billion, a 25.6% increase. Janus Henderson Group PLC cut its position by 2,537,006 shares, leaving it with 9,766,496 shares valued at $949.5 million, a 20.6% decrease. Baker Bros. Advisors LP added 100,000 shares, bringing its total to 9,555,357 shares, a modest 1.1% increase. Notably, Vanguard Capital Management LLC opened a new position with 8,362,284 shares valued at about $813.2 million.
Revolution Medicines, Inc. Stock Down 9.9%
Shares of Revolution Medicines, Inc. traded near $192.62 on Tuesday. The company, which focuses on precision oncology therapies, has a market cap of around $38.7 billion. It has a beta of 1.407, indicating moderate volatility compared to the market. The stock has a 52-week low of $34.00 and a high of $184.39, with moving averages of $151.23 for 50 days and $98.50 for 200 days. Additionally, the firm maintains a strong liquidity position with a current ratio of 6.795 and a quick ratio of 6.589, while its debt-to-equity ratio stands at 29.153.
$RVMD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Revolution Medicines, Inc.
Insider trading activity at Revolution Medicines revealed several transactions. On June 24, 2026, Chief Financial Officer Anders Jack executed both planned and unplanned trades, buying 20,000 shares at an unspecified price and selling another 20,000 shares at an average price of $168.33. Additionally, Anders Jack purchased 20,000 shares at $18.56. On June 18, 2026, insiders Lorence Kim, Flavia Borellini, and Sushil Patel each bought 3,127 shares at no disclosed price.
Analysts Set New Price Targets
Truist Securities maintained its buy rating on June 30, 2026, with a $210 price target. Other analysts have also shown optimism. On June 29, 2026, Needham maintained a buy rating with a target of $235. Evercore ISI Group reiterated a buy rating with a $220 target on June 10, 2026. RBC Capital and HC Wainwright & Co. also maintained buy ratings with targets of $182 and $195, respectively, earlier in June. The consensus among analysts is a strong buy, with an average target price of $188.57 based on 21 opinions.
About Revolution Medicines
Revolution Medicines, Inc. is a biotech company based in Redwood City, California. It focuses on developing targeted therapies for RAS-driven cancers. Led by CEO Dr. Mark A. Goldsmith, the company is advancing a pipeline of RAS(ON) inhibitors and companion inhibitors aimed at treating various solid tumors. With 883 employees, Revolution Medicines is committed to addressing unmet needs in oncology through innovative research and development.
Bottom Line
Truist Securities' reaffirmation of a buy rating and a $210 target for Revolution Medicines underscores confidence in the company's growth potential. Investors continue to monitor institutional and insider activities, which provide insights into market sentiment. As a clinical-stage biotech firm, Revolution Medicines remains a point of interest for those tracking advancements in cancer therapies.
Get Revolution Medicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RVMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.